Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database - PubMed (original) (raw)

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

Nehal N Mehta et al. Eur Heart J. 2010 Apr.

Abstract

Aims: Psoriasis is a common chronic inflammatory T-helper cell-1/17 mediated skin disease. Recent studies suggest that psoriasis, particularly if severe, may be an independent risk factor for atherosclerosis, myocardial infarction (MI), and stroke. We conducted a cohort study using the General Practice Research Database to determine if severe psoriasis patients have an increased risk of cardiovascular (CV) mortality.

Methods and results: Severe psoriasis was defined as patients who received a psoriasis diagnosis and systemic therapy consistent with severe psoriasis (n = 3603). Up to four unexposed patients without psoriasis were selected from the same practices and start dates for each psoriasis patient (n = 14 330). For every death, the cause was determined by review of the electronic medical record. Severe psoriasis was an independent risk factor for CV mortality (HR 1.57; 95% CI 1.26, 1.96) when adjusting for age, sex, smoking, diabetes, hypertension, and hyperlipidaemia. Overall, severe psoriasis patients experienced one extra CV death per 283 patients per year, even when adjusting for major CV risk factors. The relative risk of CV mortality was modified by age. For example, the RR of CV death for a 40-year-old and 60-year-old with severe psoriasis was 2.69 (1.45, 4.99) and 1.92 (1.41, 2.62), respectively. The findings were robust to multiple sensitivity analyses.

Conclusion: Patients with severe psoriasis have an increased risk of CV mortality that is independent of traditional CV risk factors. Additional studies are needed to determine the mechanism of this association and the impact that control of psoriasis has on CV risk.

PubMed Disclaimer

Comment in

Psoriasis, inflammation, and vascular risk: a problem more than skin deep?
Ridker PM. Ridker PM. Eur Heart J. 2010 Apr;31(8):902-4. doi: 10.1093/eurheartj/ehq042. Epub 2010 Mar 9. Eur Heart J. 2010. PMID: 20215124 No abstract available.

Cited by

Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation.
Golden JB, Groft SG, Squeri MV, Debanne SM, Ward NL, McCormick TS, Cooper KD. Golden JB, et al. J Immunol. 2015 Sep 1;195(5):2006-18. doi: 10.4049/jimmunol.1402307. Epub 2015 Jul 29. J Immunol. 2015. PMID: 26223654 Free PMC article.
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders.
Weber BN, Stevens E, Perez-Chada LM, Brown JM, Divakaran S, Bay C, Bibbo C, Hainer J, Dorbala S, Blankstein R, Taqueti VR, Merola JF, Massarotti E, Costenbader K, Liao K, Di Carli MF. Weber BN, et al. JACC Cardiovasc Imaging. 2021 Nov;14(11):2212-2220. doi: 10.1016/j.jcmg.2020.12.031. Epub 2021 Mar 17. JACC Cardiovasc Imaging. 2021. PMID: 33744132 Free PMC article.
Psoriasis: classical and emerging comorbidities.
Oliveira Mde F, Rocha Bde O, Duarte GV. Oliveira Mde F, et al. An Bras Dermatol. 2015 Jan-Feb;90(1):9-20. doi: 10.1590/abd1806-4841.20153038. An Bras Dermatol. 2015. PMID: 25672294 Free PMC article. Review.
Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study.
Uceda DE, Dey AK, Lateef SS, Abdelrahman K, Aksentijevich M, Reddy AS, Choi H, Rodante JA, Playford MP, Bluemke DA, Zhou W, Chen MY, Gelfand JM, Mehta NN. Uceda DE, et al. J Invest Dermatol. 2021 Apr;141(4):913-916. doi: 10.1016/j.jid.2020.07.037. Epub 2020 Oct 1. J Invest Dermatol. 2021. PMID: 33011154 Free PMC article. No abstract available.
Effects of Dietary Protein Intake on Cutaneous and Systemic Inflammation in Mice with Acute Experimental Psoriasis.
Knopp T, Bieler T, Jung R, Ringen J, Molitor M, Jurda A, Münzel T, Waisman A, Wenzel P, Karbach SH, Wild J. Knopp T, et al. Nutrients. 2021 May 31;13(6):1897. doi: 10.3390/nu13061897. Nutrients. 2021. PMID: 34072973 Free PMC article.

References

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–1541. - PubMed
1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60:218–224. - PMC - PubMed
1. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708. - PubMed
1. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–1499. - PubMed
1. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416–422. - PMC - PubMed

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database - PubMed (original) (raw)